Designing drug delivery devices: Prioritizing simplicity, empathy and real patient needs
Rick Wedge shares his personal and professional journey from developing medical devices to becoming a patient dependent on diabetes technology, following a total pancreatectomy and diagnosis of Type 3C diabetes.
The discussion covers the challenges of managing diabetes, the importance of wearables and continuous glucose monitoring, and the impact of technology on quality of life.
Unveiling dsRNA Impurities in mRNA Therapeutics 11:00-12:00 EST | 16:00-17:00 GMT | 19:00-21:00 CET 4 February 2026
In this webinar we will discuss why dsRNA is undesirable as it can negatively impact the efficacy of mRNA products and patient safety by triggering various cascades in the innate immune system, typically associated with the response to virally infected cells.
Reconfiguring biopharmaceutical manufacturing: Evaluating the multi-modal paradigm 10:00-11:00 EST | 15:00-16:00 GMT | 16:00-17:00 CET 19 February 2026
This presentation is intended for professionals involved in biopharmaceutical manufacturing, facility design, and strategic operations. Attendees will benefit from practical frameworks, case studies, and strategic insights to guide decision-making around multi-modal manufacturing adoption.
RNA Delivery Technologies 11:00-12:00 EST | 16:00-17:00 GMT | 19:00-21:00 CET 25 February 2026
This industry review compares technologies—LNPs, liposomes, exosomes, polymers—highlighting their strengths, limitations, and manufacturing complexities. It emphasizes the need for scalable, stable, and targeted delivery systems to unlock RNA’s promise across diverse clinical applications.
Himani Singh from Ecolab and BioPhorum representatives are chairing three sessions across the event:
Roundtable Session 1 – Table 16 - Use of machine Learning (ML) and artificial intelligence in content creation of early phase development and managing submissions and information requests with health authorities
Roundtable Session 1 – Table 1 - Recent trends in questions from Health Authorities
Roundtable Session 2 – Table 12 - Method development, use of artificial intelligence for process and analytics